Clinical Trials Browser

INDUSTRY × Carcinoma, Non-Small-Cell Lung × ARQ 197 × Clear all

NCT01178411 2021-03-10

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

Phase 1/2 Completed

60 enrolled 11 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT01395758 2018-04-03

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

96 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT01069757 2017-03-15

A Study of ARQ 197 in Combination With Erlotinib

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01251796 2017-03-15

A Study of ARQ 197 in Combination With Erlotinib

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01377376 2016-12-07

ATTENTION

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01580735 2015-08-18

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

NCT00777309 2013-02-28

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung